Hagens Berman Investigates uniQure Amidst FDA Criticism and Allegations of Misleading Data
Hagens Berman's Investigation into uniQure: What Investors Need to Know
The national law firm, Hagens Berman, has recently expanded its investigation into uniQure N.V. (NASDAQ: QURE) following public rebukes from the Food and Drug Administration (FDA) over serious allegations of misleading clinical data. This investigation comes on the heels of a securities class action lawsuit that aims to safeguard investors who purchased uniQure shares within a specified period.
Background of the Issue
During a media briefing on March 5-6, 2026, FDA officials expressed serious concerns about uniQure's lead gene therapy candidate, AMT-130. A spokesperson labeled it a
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.